Loading
People known for designing and leading clinical trials. 160 records carry it: 160 people.
| Cancers | Other tags | ||||
|---|---|---|---|---|---|
A. Oliver Sartor Professor of Medical Oncology and Urology, Mayo Clinic · Mayo Clinic Led VISION, the trial that made lutetium-PSMA the first radioligand therapy for prostate cancer. | Prostate cancer | none | prostate, radioligand | ||
Aditya Bardia Professor of Medicine and Director of Translational Research Integration, UCLA Jonsson Comprehensive Cancer Center · UCLA Jonsson Comprehensive Cancer Center Led ASCENT, the trial that made sacituzumab govitecan the first ADC for triple-negative breast cancer, and the EMERALD trial of elacestrant. | Triple-negative breast cancer, HR-positive / HER2-negative breast cancer | none | breast, adc | ||
Alastair Greystoke Professor of Precision Oncology, Newcastle University; Consultant Medical Oncologist, Northern Centre for Cancer Care; Clinical Director for Cancer, North East and Yorkshire Genomic Medicine Service · Newcastle Cancer Centre / Northern Centre for Cancer Care The Newcastle oncologist who led the NHS England pilot that put a blood test for lung cancer mutations into the diagnostic pathway, and who co-leads the CONCORDE radiotherapy platform. | Non-small-cell lung cancer, Lung cancer | none | lung, uk, genomics | ||
Aleksandar Sekulic Dermatologist, Mayo Clinic Comprehensive Cancer Center in Arizona · Mayo Clinic Comprehensive Cancer Center in Arizona Mayo Clinic dermatologist who led ERIVANCE, the trial that established vismodegib, the first Hedgehog pathway inhibitor, for advanced basal cell carcinoma. | Locally advanced and metastatic basal cell carcinoma, Skin cancer | none | skin, targeted-therapy | ||
Alice P. Chen Medical oncologist, Division of Cancer Treatment and Diagnosis, National Cancer Institute · National Cancer Institute (NIH) NCI oncologist who led the trial that showed atezolizumab produces lasting responses in alveolar soft part sarcoma, the first approved treatment for this rare cancer. | Alveolar soft part sarcoma, Sarcomas | none | sarcoma, rare-cancers, immunotherapy | ||
Alice T. Shaw Thoracic oncologist and drug developer Lung cancer doctor whose trials at Massachusetts General Hospital showed that crizotinib works in ROS1-rearranged lung cancer and defined how ALK-positive tumours become resistant to targeted drugs. | ROS1-positive non-small-cell lung cancer, Non-small-cell lung cancer, Lung cancer | none | lung, targeted-therapy | ||
Amanda Nickles Fader Gynaecologic oncologist, Johns Hopkins · Johns Hopkins Hospital / Sidney Kimmel Comprehensive Cancer Center Baltimore gynaecologic oncologist who led the trial showing that adding trastuzumab to chemotherapy helps women with HER2-positive uterine serous carcinoma, an aggressive form of endometrial cancer. | p53-abnormal endometrial cancer, including uterine serous carcinoma, Endometrial cancer | none | endometrial, gynaecological | ||
Amer M. Zeidan Haematologist, Yale Cancer Center · Yale Cancer Center / Smilow Cancer Hospital Yale haematologist who led VERONA, the trial that asked whether adding venetoclax to azacitidine helps people with higher-risk myelodysplastic syndromes, and found it did not lengthen survival. | Higher-risk myelodysplastic syndromes, Myelodysplastic syndromes / neoplasms | none | mds | ||
Ana Oaknin Head of the Gynaecological Cancer Programme, Vall d'Hebron Institute of Oncology, Barcelona · Vall d'Hebron University Hospital / VHIO Barcelona oncologist who led GARNET, the trial that brought dostarlimab to mismatch repair-deficient endometrial cancer, and who has led many trials of new drugs for gynaecological cancers. | Mismatch-repair-deficient endometrial cancer, Endometrial cancer, Cervical cancer | none | endometrial, gynaecological, immunotherapy | ||
Andrea DeCensi Medical oncologist, E.O. Ospedali Galliera, Genoa · E.O. Ospedali Galliera Italian oncologist who led TAM-01, the trial that showed a low dose of tamoxifen halves recurrence after non-invasive breast cancer with fewer side effects than the standard dose. | Ductal carcinoma in situ, Breast cancer | none | breast, prevention | ||
Andrea Sartore-Bianchi Medical oncologist, Niguarda Cancer Center and University of Milan · Niguarda Cancer Center, ASST Grande Ospedale Metropolitano Niguarda Milan oncologist who was lead author of HERACLES, the first trial to show that HER2-targeted drugs work in HER2-amplified colorectal cancer. | HER2-amplified colorectal cancer, Colorectal cancer | none | colorectal, targeted-therapy | ||
Andrew B. Lassman Chief of Neuro-Oncology, Columbia University Irving Medical Center · Herbert Irving Comprehensive Cancer Center, Columbia University New York neuro-oncologist who led INTELLANCE-1, the trial that tested the EGFR-directed antibody-drug conjugate depatuxizumab mafodotin in newly diagnosed glioblastoma and found it did not extend survival. | Glioma & glioblastoma, Brain and spinal cord tumours | none | brain | ||
Andrew J. Armstrong Professor of Medicine, Surgery, and Pharmacology and Cancer Biology, Duke Cancer Institute · Duke Cancer Institute Led ARCHES, which established enzalutamide with hormone therapy for metastatic hormone-sensitive prostate cancer. | Prostate cancer | none | prostate | ||
Andrew J. Wagner Sarcoma medical oncologist, Dana-Farber Cancer Institute · Dana-Farber Brigham Cancer Center Boston sarcoma doctor who first showed that mTOR inhibitors shrink perivascular epithelioid cell tumours and then led AMPECT, the trial that made nab-sirolimus the first approved treatment for these rare cancers. | Perivascular epithelioid cell tumour, Sarcomas | none | sarcoma, rare-cancers, targeted-therapy | ||
Andrew X. Zhu Hepatobiliary medical oncologist and trial lead Oncologist who led REACH-2, the first positive biomarker-selected trial in liver cancer, which established ramucirumab for patients with a high alpha-fetoprotein level. | Advanced hepatocellular carcinoma, Hepatocellular carcinoma, Intrahepatic cholangiocarcinoma | none | hcc, biliary | ||
Angela Lamarca Medical oncologist, biliary tract and neuroendocrine cancers Oncologist who was lead author of ABC-06, the first randomised trial to show that second-line chemotherapy helps people with advanced bile duct cancer. | Biliary tract cancer, Biliary tract cancer, Neuroendocrine tumours | none | biliary | ||
Anthony C. Nichols Head and neck surgeon, Western University and London Health Sciences Centre, Ontario · Verspeeten Family Cancer Centre, London Health Sciences Centre Canadian surgeon who led ORATOR, the first randomised trial to compare robotic surgery with radiotherapy for early throat cancer, which found swallowing was slightly better after radiotherapy. | HPV-positive oropharyngeal cancer, Oropharyngeal cancer, Head and neck squamous cell carcinoma | none | head-and-neck, surgery | ||
Antoine Italiano Head of Early-Phase Trials and Sarcoma Unit, Institut Bergonié, Bordeaux · Institut Bergonié Bordeaux oncologist who led CABONE, the trial that showed cabozantinib shrinks or stabilises osteosarcoma and Ewing sarcoma after standard treatment has failed. | Osteosarcoma, Ewing sarcoma, Sarcomas | none | sarcoma, early-phase | ||
Brian I. Rini Chief of Clinical Trials, Vanderbilt-Ingram Cancer Center; Ingram Professor of Cancer Research · Vanderbilt-Ingram Cancer Center Led KEYNOTE-426, which made pembrolizumab plus axitinib a first-line standard for kidney cancer. | Renal cell carcinoma | none | rcc, immunotherapy | ||
Caroline Robert Head of Dermatology Unit, Gustave Roussy; Professor, Paris-Saclay University · Gustave Roussy Led KEYNOTE-006 and COMBI-v, the trials that made pembrolizumab and dabrafenib-trametinib standards in melanoma. | Melanoma | none | melanoma, immunotherapy | ||
Caron A. Jacobson Lymphoma specialist and medical director of immune effector cell therapy, Dana-Farber Cancer Institute · Dana-Farber Brigham Cancer Center Boston lymphoma doctor who led ZUMA-5, the trial that brought the CAR-T therapy axicabtagene ciloleucel to relapsed follicular lymphoma. | Follicular lymphoma, Marginal zone lymphoma, Non-Hodgkin lymphoma | none | lymphoma, car-t, cell-therapy | ||
Chris C. Parker Clinical oncologist, The Royal Marsden and The Institute of Cancer Research · The Royal Marsden London radiation oncologist who led ALSYMPCA, the trial that showed radium-223 lengthens survival in prostate cancer that has spread to bone, and RADICALS-RT, which showed radiotherapy after prostatectomy can safely wait until the PSA rises. | Metastatic castration-resistant prostate cancer, Biochemical recurrence of prostate cancer, Prostate cancer | none | prostate, radiotherapy | ||
Christopher J. Sweeney Director, South Australian Immunogenomics Cancer Institute; Professor, University of Adelaide · South Australian immunoGENomics Cancer Institute (SAiGENCI), University of Adelaide Led CHAARTED, which showed adding docetaxel to hormone therapy extends survival in newly metastatic prostate cancer. | Prostate cancer | none | prostate, ecog-acrin | ||
Courtney D. DiNardo Professor of Leukemia, MD Anderson Cancer Center · MD Anderson Cancer Center Led VIALE-A, which made venetoclax plus azacitidine the standard for older patients with acute myeloid leukaemia. | Acute myeloid leukaemia | none | aml, venetoclax | ||
Daniel Palmer Professor of Medical Oncology, University of Liverpool; Director, CRUK and NIHR Liverpool Experimental Cancer Medicine Centre; GIRFT joint clinical lead for pancreatic cancer · Liverpool University Hospitals HPB centre (Aintree) Liverpool medical oncologist, second author of ESPAC-4 and co-lead of ESPAC5, who directs the Liverpool Experimental Cancer Medicine Centre and leads the national GIRFT review of pancreatic cancer services. | Pancreatic ductal adenocarcinoma, Hepatocellular carcinoma, Biliary tract cancer | none | pancreatic, uk, girft | ||
Danny Rischin Medical oncologist and Director of Medical Oncology, Peter MacCallum Cancer Centre · Peter MacCallum Cancer Centre Melbourne oncologist who led C-POST, the trial that showed cemiplimab after surgery and radiotherapy cuts recurrence in high-risk cutaneous squamous-cell carcinoma. | Advanced cutaneous squamous cell carcinoma, Head and neck squamous cell carcinoma, Skin cancer | none | skin, head-and-neck, immunotherapy | ||
Darren R. Hargrave Paediatric neuro-oncologist, Great Ormond Street Hospital and UCL Great Ormond Street Institute of Child Health · Great Ormond Street Hospital for Children London paediatric neuro-oncologist who led the trial showing that dabrafenib and trametinib work in children with BRAF V600-mutant high-grade glioma. | Paediatric high-grade glioma, Childhood cancers | none | paediatric, brain, targeted-therapy | ||
David Dearnaley Emeritus Professor of Uro-Oncology, The Institute of Cancer Research and The Royal Marsden · The Institute of Cancer Research British radiation oncologist who led CHHiP, the trial that showed prostate cancer can be treated in 20 radiotherapy sessions rather than 37 with the same results, changing practice worldwide. | Localised prostate cancer, intermediate risk, Prostate cancer | none | prostate, radiotherapy | ||
David M. Gershenson Gynaecologic oncologist, MD Anderson Cancer Center · MD Anderson Cancer Center Houston gynaecologic oncologist who defined low-grade serous ovarian cancer as a distinct disease and led GOG 281, the trial that showed the MEK inhibitor trametinib works better than standard treatments for it. | Low-grade serous ovarian cancer, Ovarian cancer | none | ovarian, gynaecological | ||
David Sebag-Montefiore Professor of Clinical Oncology (Audrey and Stanley Burton Chair), University of Leeds; Clinical Director, Leeds Clinical Trials Research Unit · Leeds Cancer Centre, St James's University Hospital The Leeds clinical oncologist who led CR07, the trial that made short-course radiotherapy before surgery the standard for rectal cancer, and who now works on preserving the rectum instead of removing it. | Colorectal cancer, Rectal cancer | none | colorectal, uk, radiotherapy | ||
Dion Morton Barling Professor of Surgery, University of Birmingham · University Hospitals Birmingham / University of Birmingham Cancer Research Centre The Birmingham surgeon who chairs FOxTROT and runs the surgical trials programme that tests how bowel cancer operations are done, not just which drugs come with them. | Colorectal cancer, Rectal cancer | none | colorectal, surgeon, uk | ||
E. Shelley Hwang Breast surgical oncologist, Duke Cancer Institute · Duke Cancer Institute Duke surgeon who led COMET, the trial testing whether women with low-risk DCIS can safely be monitored instead of having surgery straight away. | Ductal carcinoma in situ, Breast cancer | none | breast, surgery, de-escalation | ||
Eric Jonasch Genitourinary medical oncologist, MD Anderson Cancer Center · MD Anderson Cancer Center Houston oncologist who led the trial that established belzutifan, the first drug for the tumours of von Hippel-Lindau disease, including kidney cancers, pancreatic tumours and haemangioblastomas. | Spinal cord tumours, Clear cell renal cell carcinoma, Renal cell carcinoma | none | kidney, targeted-therapy | ||
Florence Duffaud Medical oncologist, Hôpital de la Timone, Aix-Marseille University · Hôpital de la Timone, Assistance Publique-Hôpitaux de Marseille Marseille oncologist who led REGOBONE, the trial that showed regorafenib delays progression in metastatic osteosarcoma and other bone sarcomas. | Osteosarcoma, Ewing sarcoma, Chondrosarcoma | none | sarcoma | ||
Francesco Lo-Coco Haematologist, University of Rome Tor Vergata (died 2019) Italian haematologist who led APL0406, the trial that showed acute promyelocytic leukaemia can be cured with all-trans retinoic acid and arsenic trioxide alone, without chemotherapy. | Acute promyelocytic leukaemia, Acute myeloid leukaemia | none | leukaemia | ||
Fred Saad Professor and Chief of Urology, Centre hospitalier de l'Université de Montréal · Centre hospitalier de l'Université de Montréal (CHUM) Montreal urologist who led the zoledronic acid trials in prostate cancer bone metastases and was lead author of ARANOTE, which established darolutamide plus hormone therapy for metastatic hormone-sensitive disease. | Metastatic hormone-sensitive prostate cancer, Metastatic castration-resistant prostate cancer, Prostate cancer | none | prostate | ||
Gabriel N. Hortobagyi Professor of Breast Medical Oncology, MD Anderson Cancer Center · MD Anderson Cancer Center Breast oncologist who led MONALEESA-2, the first CDK4/6 trial to show an overall survival gain in first-line HR-positive disease. | HR-positive / HER2-negative breast cancer | none | breast | ||
Gary Middleton Professor of Medical Oncology, University of Birmingham; Honorary Consultant Oncologist, University Hospitals Birmingham; Director of the Birmingham Experimental Cancer Medicine Centre · University Hospitals Birmingham / University of Birmingham Cancer Research Centre The Birmingham oncologist who ran the National Lung Matrix Trial, the largest umbrella trial in lung cancer, and published the honest answer: most drug-biomarker pairs did not work. | Non-small-cell lung cancer, Lung cancer, KRAS G12C-mutant non-small-cell lung cancer | none | lung, uk | ||
Gerald W. Prager Gastrointestinal medical oncologist, Medical University of Vienna · Comprehensive Cancer Center Vienna, Medical University of Vienna / AKH Vienna oncologist who was lead author of SUNLIGHT, the trial that showed adding bevacizumab to trifluridine-tipiracil lengthens survival in refractory colorectal cancer. | KRAS G12C-mutant colorectal cancer, Colorectal cancer | none | colorectal | ||
Gerhardt Attard Medical oncologist, UCL Cancer Institute and University College London Hospitals · University College London Hospitals / UCL Cancer Institute London oncologist who helped develop abiraterone and led the STAMPEDE analysis showing that two years of abiraterone alongside hormone therapy and radiotherapy improves survival in high-risk localised prostate cancer. | Localised prostate cancer, high and very high risk, Prostate cancer | none | prostate | ||
Ghassan K. Abou-Alfa Attending Physician, Gastrointestinal Oncology, Memorial Sloan Kettering Cancer Center · Memorial Sloan Kettering Cancer Center Led HIMALAYA and ClarIDHy, which gave liver cancer a dual-immunotherapy option and biliary cancer its first targeted drug. | Hepatocellular carcinoma, Biliary tract cancer | none | hcc, biliary | ||
Giles W. Robinson Paediatric neuro-oncologist, St. Jude Children's Research Hospital · St. Jude Children's Research Hospital Memphis paediatric neuro-oncologist who led the study showing that the Hedgehog inhibitor vismodegib helps only adults and older children whose medulloblastoma belongs to the SHH subgroup, an early example of subgroup-directed brain tumour therapy. | SHH-activated medulloblastoma, Medulloblastoma, Childhood cancers | none | paediatric, brain, targeted-therapy | ||
Gilles Salles Chief, Lymphoma Service, Memorial Sloan Kettering Cancer Center · Memorial Sloan Kettering Cancer Center Led PRIMA, which established rituximab maintenance in follicular lymphoma, and co-chaired POLARIX in DLBCL. | Follicular lymphoma, Diffuse large B-cell lymphoma | none | lymphoma, lysa | ||
Gregory J. Riely Thoracic medical oncologist, Memorial Sloan Kettering Cancer Center · Memorial Sloan Kettering Cancer Center Lung cancer doctor who led PHAROS, the trial that brought the encorafenib and binimetinib pair to BRAF V600E-mutant lung cancer. | BRAF V600E-mutant non-small-cell lung cancer, Non-small-cell lung cancer, Lung cancer | none | lung, targeted-therapy | ||
H. Miles Prince Haematologist, Peter MacCallum Cancer Centre and Epworth Healthcare, Melbourne · Peter MacCallum Cancer Centre Melbourne haematologist who led ALCANZA, the trial that showed brentuximab vedotin beats standard treatment for CD30-expressing cutaneous T-cell lymphoma. | Cutaneous T-cell lymphoma, Peripheral T-cell lymphomas | none | lymphoma | ||
Hansjochen Wilke Medical oncologist, Kliniken Essen-Mitte · Kliniken Essen-Mitte German oncologist who led RAINBOW, the trial that made ramucirumab plus paclitaxel a standard second-line treatment for advanced stomach cancer. | PD-L1-high gastric cancer, Gastric & gastro-oesophageal junction cancer | none | gastric | ||
Heikki Joensuu Professor of Oncology, Helsinki University Hospital · HUS Comprehensive Cancer Center, Helsinki University Hospital Finnish oncologist who treated the first GIST patient with imatinib in 2000 and led SSG XVIII, the trial that showed three years of adjuvant imatinib beats one year after surgery for high-risk GIST. | KIT exon 11-mutant GIST, Gastrointestinal stromal tumour, Sarcomas | none | gist | ||
Hervé Dombret Haematologist, Hôpital Saint-Louis (AP-HP), Paris · Cancer Institute AP-HP Nord, Université Paris Cité Paris haematologist who led AZA-AML-001, the trial that showed azacitidine can extend survival for older people with acute myeloid leukaemia who cannot have intensive chemotherapy. | Acute myeloid leukaemia in older or unfit patients, Acute myeloid leukaemia | none | leukaemia | ||
Hitoshi Katai Gastric surgeon, National Cancer Center Hospital, Tokyo · National Cancer Center Hospital Japanese surgeon who led JCOG0912, the trial that confirmed laparoscopic gastrectomy is not inferior to open surgery for early stomach cancer. | Early gastric cancer, Gastric & gastro-oesophageal junction cancer | none | gastric, surgery | ||
Hyung-Ho Kim Gastric surgeon, Seoul National University Bundang Hospital · Seoul National University Bundang Hospital Korean surgeon who led KLASS-01, the trial that showed keyhole gastrectomy is as safe and effective as open surgery for early stomach cancer. | Early gastric cancer, Gastric & gastro-oesophageal junction cancer | none | gastric, surgery | ||
Hywel Williams Professor of Dermato-Epidemiology and Co-Director of the Centre of Evidence Based Dermatology, University of Nottingham The Nottingham epidemiologist who founded British evidence-based dermatology and ran the trial that answered whether a cream can replace surgery for the commonest cancer there is. | Basal cell carcinoma, Skin cancer | none | uk, skin, dermatology | ||
Ian Chau Consultant Medical Oncologist, The Royal Marsden; Professor, The Institute of Cancer Research · The Royal Marsden A Royal Marsden gastrointestinal oncologist who has shaped UK colorectal and upper gastrointestinal trials and who works on the blood test for residual disease after bowel surgery. | Colorectal cancer | none | colorectal, uk | ||
Inge M. van der Sluis Paediatric oncologist, Princess Máxima Center for Pediatric Oncology · Princess Máxima Center for Pediatric Oncology Dutch paediatric oncologist who led the study showing that adding one course of blinatumomab to chemotherapy sharply improves survival for babies with KMT2A-rearranged leukaemia. | Infant acute lymphoblastic leukaemia, Acute lymphoblastic leukaemia, Childhood cancers | none | paediatric, leukaemia, immunotherapy | ||
Jacques Grill Paediatric neuro-oncologist, Gustave Roussy · Gustave Roussy Paris paediatric neuro-oncologist who led HERBY, the trial that showed adding bevacizumab does not help children with high-grade glioma, and who leads European trials in diffuse midline glioma. | Paediatric high-grade glioma, Glioma & glioblastoma, Childhood cancers | none | paediatric, brain | ||
James C. Yao Chair, Department of Gastrointestinal Medical Oncology, MD Anderson Cancer Center · MD Anderson Cancer Center Led the RADIANT trials that made everolimus a standard therapy for pancreatic and other neuroendocrine tumours. | Neuroendocrine tumours | none | neuroendocrine, mtor | ||
Jan A. Burger Haematologist, MD Anderson Cancer Center · MD Anderson Cancer Center Leukaemia specialist who was lead author of RESONATE-2, the trial that made ibrutinib a first-line treatment for chronic lymphocytic leukaemia in older patients. | Chronic lymphocytic leukaemia, first treatment, Chronic lymphocytic leukaemia | none | leukaemia, targeted-therapy | ||
Jan C. Buckner Medical oncologist, Mayo Clinic · Mayo Clinic Mayo Clinic neuro-oncologist who was lead author of the long-term RTOG 9802 results, which showed that adding PCV chemotherapy to radiotherapy roughly doubles survival in high-risk low-grade glioma. | Astrocytoma, IDH-mutant, Oligodendroglioma, IDH-mutant and 1p/19q-codeleted, Brain and spinal cord tumours | none | brain | ||
Jean Abraham Professor of Precision Breast Cancer Medicine and Honorary Consultant in Medical Oncology, University of Cambridge; Director, Precision Breast Cancer Institute; Consultant, Addenbrooke's Hospital · Addenbrooke's Hospital, Cambridge University Hospitals Chief investigator of PARTNER, the UK trial of neoadjuvant olaparib with platinum chemotherapy in triple-negative and BRCA-associated breast cancer, run from Addenbrooke's across 23 NHS sites (30 on the ClinicalTrials.gov record). | Triple-negative breast cancer, Early triple-negative breast cancer | none | breast, uk | ||
Jean-Jacques Grob Professor of Dermatology, Aix-Marseille University, Hôpital de la Timone · Hôpital de la Timone, Assistance Publique-Hôpitaux de Marseille Marseille dermatologist who led KEYNOTE-629, which established pembrolizumab for advanced cutaneous squamous-cell carcinoma, and who has been a senior investigator on many European melanoma trials. | Advanced cutaneous squamous cell carcinoma, Melanoma, Skin cancer | none | skin, melanoma, immunotherapy | ||
Jean-Pascal Machiels Head of Medical Oncology, Cliniques universitaires Saint-Luc, Brussels · King Albert II Cancer Institute, Cliniques universitaires Saint-Luc Brussels oncologist who led KEYNOTE-412, the trial that tested adding pembrolizumab to chemoradiotherapy for locally advanced head and neck cancer. | HPV-negative head and neck squamous cell carcinoma, Head and neck squamous cell carcinoma | none | head-and-neck, immunotherapy |
The table above loads 60 of 160 records first and fetches the rest as you scroll, search or filter. This tag as JSON · table rows · API